Palisade Bio (NASDAQ:PALI) Upgraded to Strong-Buy at Piper Sandler

Piper Sandler upgraded shares of Palisade Bio (NASDAQ:PALI) to a strong-buy rating in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has $25.00 price target on the stock.

Several other equities analysts also recently commented on PALI. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a report on Tuesday, November 11th. Finally, Wall Street Zen downgraded shares of Palisade Bio from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palisade Bio has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Palisade Bio Trading Up 15.3%

PALI opened at $2.48 on Monday. The firm’s 50 day simple moving average is $1.95 and its two-hundred day simple moving average is $1.28. The company has a market capitalization of $369.52 million, a PE ratio of -1.17 and a beta of 1.54. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.59.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). Equities analysts forecast that Palisade Bio will post -12.43 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.